dr. hamid on a potential biomarker of response to docetaxel in mhspc
Published 4 years ago • 77 plays • Length 1:17Download video MP4
Download video MP3
Similar videos
-
1:15
dr. hamid on tmb as a biomarker for immunotherapy response in melanoma
-
1:31
dr. hamid on the exploration of predictive biomarkers in mhspc subtypes
-
1:19
dr. hamid on using biomarkers for immunotherapy in melanoma
-
3:16
chaarted: luminal b subtype as a biomarker of docetaxel benefit for mhspc
-
1:06
dr. hamid on the progression of therapy for metastatic prostate cancer
-
1:17
dr. oh on the safety profile of docetaxel in prostate cancer
-
2:32
dr. hamid on a retrospective analysis of pembrolizumab in melanoma
-
1:43
dr. oh on the role of docetaxel in metastatic hormone-sensitive prostate cancer
-
1:19
role of the addition of docetaxel to adt in mhspc
-
1:10
dr. oh on the use of abiraterone and docetaxel in mcrpc
-
1:07
dr. penson on treatment selection in metastatic hormone-sensitive prostate cancer
-
1:37
recent advances in mhspc: 177lu-psma-617, propel and biomarker-directed strategies
-
1:22
dr. bryce on the use of abiraterone versus docetaxel in patients with prostate cancer
-
1:43
daniel m. geynisman, md, on the real-world analysis of abiraterone acetate & docetaxel in mhspc
-
1:14
dr. dreicer on abiraterone and enzalutamide in prostate cancer
-
0:42
dr. rathkopf on ar-v7 biomarker in prostate cancer
-
2:01
ascogu24: xiao wei, md on tps244 | dana-farber cancer institute
-
1:44
arasens: the addition of darolutamide to adt and docetaxel for the treatment of mhspc
-
1:41
dr. oh on abiraterone versus docetaxel in prostate cancer